[go: up one dir, main page]

IL84729A0 - Preparation of a vaccine against hepatitis b and the vaccine obtained thereby - Google Patents

Preparation of a vaccine against hepatitis b and the vaccine obtained thereby

Info

Publication number
IL84729A0
IL84729A0 IL84729A IL8472987A IL84729A0 IL 84729 A0 IL84729 A0 IL 84729A0 IL 84729 A IL84729 A IL 84729A IL 8472987 A IL8472987 A IL 8472987A IL 84729 A0 IL84729 A0 IL 84729A0
Authority
IL
Israel
Prior art keywords
vaccine
preparation
zonal
subjected
against hepatitis
Prior art date
Application number
IL84729A
Other versions
IL84729A (en
Original Assignee
Pasteur Vaccins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Vaccins filed Critical Pasteur Vaccins
Publication of IL84729A0 publication Critical patent/IL84729A0/en
Publication of IL84729A publication Critical patent/IL84729A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Particles of hepatitis B virus surface antigens (HBsAg) are produced by expression from a culture of CHO cells transfected with a plasmid, recovering the culture supernatant which, after sterilising filtration, is concentrated and subjected to a fractional precipitation with PEG, the precipitate being taken up and subjected to a zonal velocity centrifugation and then to a zonal flotation centrifugation, following which chromatography is performed in an anion exchanger medium. The vaccine is noteworthy for its purity and its immunogenicity, in particular for its capacity for inducing anti-pre-S2 antibodies.
IL84729A 1986-12-10 1987-12-07 Preparation of a vaccine against hepatitis b and the vaccine obtained thereby IL84729A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8617265A FR2608052B1 (en) 1986-12-10 1986-12-10 PROCESS FOR THE PREPARATION OF A HEPATITIS B VACCINE AND VACCINE OBTAINED

Publications (2)

Publication Number Publication Date
IL84729A0 true IL84729A0 (en) 1988-05-31
IL84729A IL84729A (en) 1993-02-21

Family

ID=9341743

Family Applications (1)

Application Number Title Priority Date Filing Date
IL84729A IL84729A (en) 1986-12-10 1987-12-07 Preparation of a vaccine against hepatitis b and the vaccine obtained thereby

Country Status (11)

Country Link
EP (1) EP0273811B1 (en)
JP (1) JPS63215639A (en)
KR (1) KR880007732A (en)
AT (1) ATE109353T1 (en)
CA (1) CA1306689C (en)
DE (1) DE3750330T2 (en)
DK (1) DK645687A (en)
FR (1) FR2608052B1 (en)
IL (1) IL84729A (en)
NO (1) NO171147C (en)
PT (1) PT86321B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1073604A (en) * 1991-12-01 1993-06-30 高真南 The method for preparing higher immunogenic hepatitis B vaccine
AU3269793A (en) * 1991-12-27 1993-07-28 Gensci Limited Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356413A (en) * 1971-09-09 1974-06-12 Pfizer Ltd Method of obtaining purified australia antigen from blood serum
US4088748A (en) * 1976-11-02 1978-05-09 Merck & Co., Inc. Hepatitis B surface antigen
US4162192A (en) * 1978-09-28 1979-07-24 Juridical Foundation Method for purification of HBs antigen
FR2560890B1 (en) * 1984-03-07 1987-10-16 Grp Genie Genetique COMPOSITION USEFUL FOR THE MANUFACTURE OF VACCINES CONTAINING PARTICLES CARRYING THE SURFACE ANTIGEN OF HEPATITIS B VIRUS AND THE POLYMERIZED HUMAN SERUM ALBUMIN RECEPTOR, ANIMAL CELLS CAPABLE OF PRODUCING SUCH PARTICLES
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them

Also Published As

Publication number Publication date
EP0273811A3 (en) 1988-08-03
PT86321A (en) 1988-01-01
KR880007732A (en) 1988-08-29
JPS63215639A (en) 1988-09-08
IL84729A (en) 1993-02-21
NO875142L (en) 1988-06-13
DK645687A (en) 1988-06-11
NO171147C (en) 1993-02-03
DK645687D0 (en) 1987-12-09
CA1306689C (en) 1992-08-25
PT86321B (en) 1990-11-07
DE3750330T2 (en) 1994-11-17
ATE109353T1 (en) 1994-08-15
EP0273811A2 (en) 1988-07-06
EP0273811B1 (en) 1994-08-03
NO171147B (en) 1992-10-26
NO875142D0 (en) 1987-12-09
FR2608052B1 (en) 1990-04-13
DE3750330D1 (en) 1994-09-08
FR2608052A1 (en) 1988-06-17

Similar Documents

Publication Publication Date Title
DE3280186D1 (en) SYNTHESIS OF HUMAN VIRAL ANTIGENS WITH THE AID OF YEAST.
EP0584348A4 (en) Genetic vaccine for immunodeficiency viruses
MA21911A1 (en) PROCESS FOR PRODUCING LARGE MODIFIED SURFACE PROTEIN OF HEPATITIS B VIRUS.
DE3176404D1 (en) Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
FI102616B1 (en) Method for producing a vaccine against type 3 human parainfluenza virus and expression system useful in the method
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
IL84729A0 (en) Preparation of a vaccine against hepatitis b and the vaccine obtained thereby
EP0198299A3 (en) A process for preparing hepatitis b surface antigen containing particles in novel forms which are highly immunogenic
ATE73349T1 (en) HEPATITIS SURFACE ANTIGEN PARTICLE VACCINATION.
AU4817885A (en) Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
GB2065473A (en) Process for producing hepatitis b vaccine
AU8557491A (en) Method for obtaining recombinant surface antigen of hepatitis b virus (hep b) of higher immunogenic capacity and use thereof in a vaccine preparation
EP0255242A3 (en) Oncornavirus vaccines
Gerin et al. Recombinant DNA and synthetic peptide approaches to HBV vaccine development: Immunogenicity and protective efficacy in chimpanzees.
EP0205625A1 (en) Hepatitis b virus vaccine and process for its preparation
PT69953A (en) Process for preparing a composition comprising a lyophilized herpes virus
ATE53235T1 (en) SYNTHESIS OF HUMAN VIRAL ANTIGENS USING YEAST.
Stephenne Production in yeast and mammalian cells of the first recombinant DNA human vaccine against hepatitis B: A technical and immunological comparison.
PT72045B (en) Process for preparing vaccines for swine protection
Purcell et al. the highest titers (up to 1013 particles per ml of plasma) is the 22nm spherical
JPS57209298A (en) Recombinant dna, its preparation, and host transformed therewith
KR950703054A (en) Hepatitis A Virus Vaccine (HEPATITIS A VIRUS VACCINE)
BR9705324C1 (en) Method for producing purified hbsag for vaccine preparation and recombinant vaccine against type b hepatitis
JPS57144993A (en) Preparation of human leukocyte interferon

Legal Events

Date Code Title Description
RH Patent void